Evidence map›Paper›PMID 37245145›Full record

ReviewThe Journal of investigative dermatology2023

RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.

Steven D Rhodes, Frank McCormick, Ross L Cagan, Annette Bakker, Verena Staedtke, Ina Ly, Matthew R Steensma, Sang Y Lee, Carlos G Romo, Jaishri O Blakeley and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of investigative dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Proteomic approaches for interrogating kinase signaling networks.The Journal of investigative dermatology · 2026
    Article
  2. Article
  3. Article
  4. TheCancers · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Steven D RhodesDivision of Hematology-Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA; Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Frank McCormickHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Ross L CaganSchool of Cancer Sciences, University of Glasgow, Glasgow, Scotland.
Annette BakkerChildren's Tumor Foundation, New York, New York, USA.
Verena StaedtkeDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ina LyStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Matthew R SteensmaCenter for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan, USA; Helen DeVos Children's Hospital, Spectrum Health System, Grand Rapids, Michigan, USA; College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
Sang Y LeeDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carlos G RomoDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kavita Y SarinDepartment of Dermatology, Stanford University School of Medicine, Stanford, California, USA. Electronic address: ksarin@stanford.edu.
Johns Hopkins University · USChildren's Tumor Foundation · USGrand Rapids Community College · USIndiana University Health · USMassachusetts General Hospital · USStanford Medicine · USUniversity of California, San Francisco · USUniversity of Glasgow · GB

Funding

New Ways of Targeting K-RasR35CA197709 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCORMICK, FRANK PATRICK · 2016 to 2022
$6.7M
NCI NIH HHS R35 CA197709
6 · The paper itself

Abstract

Cutaneous neurofibromas (cNFs) are the most common tumor in people with the rasopathy neurofibromatosis type 1. They number in hundreds or even thousands throughout the body, and currently, there are no effective interventions to prevent or treat these skin tumors. To facilitate the identification of novel and effective therapies, essential studies including a more refined understanding of cNF biology and the role of RAS signaling and downstream effector pathways responsible for cNF initiation, growth, and maintenance are needed. This review highlights the current state of knowledge of RAS signaling in cNF pathogenesis and therapeutic development for cNF treatment.

Indexed as

NeurofibromaNeurofibromatosis 1Skin NeoplasmsHumansSignal Transduction

Identifiers

PMID37245145
PMCPMC10409534
OpenAlexW4378550505

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.